TipRanks
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna Reports Positive One-Year Data for Miv-Cel
Company AnnouncementsKyverna Reports Positive One-Year Data for Miv-Cel
28d ago
8K
KYTX
Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG
PremiumThe Fly
Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG
28d ago
KYTX
Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
PremiumRatings
Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
2M ago
KYTX
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
PremiumThe Fly
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
2M ago
KYTX
Kyverna: Buy Rating Reaffirmed as Manufacturing Deal De‑Risks Launch Path; $33 Price Target Maintained
PremiumRatings
Kyverna: Buy Rating Reaffirmed as Manufacturing Deal De‑Risks Launch Path; $33 Price Target Maintained
3M ago
KYTX
Kyverna secures long-term miv-cel manufacturing partnership
PremiumCompany AnnouncementsKyverna secures long-term miv-cel manufacturing partnership
3M ago
8K
KYTX
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
Premium
The Fly
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
3M ago
KYTX
Kyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
Premium
Company Announcements
Kyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
3M ago
KYTX
Cue Biopharma appoints Dominic Borie as chief medical officer
PremiumThe Fly
Cue Biopharma appoints Dominic Borie as chief medical officer
3M ago
CUE
KYTX
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
PremiumThe Fly
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
3M ago
KYTX
VERA
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
PremiumCompany Announcements
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
3M ago
8K
KYTX
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
PremiumThe Fly
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
4M ago
KYTX
Kyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
PremiumRatingsKyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
5M ago
KYTX
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
Premium
Ratings
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
5M ago
KYTX
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
Premium
Ratings
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
5M ago
KYTX
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
PremiumThe Fly
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
5M ago
KYTX
Kyverna Therapeutics Stockholders Approve Directors and Auditor
PremiumCompany Announcements
Kyverna Therapeutics Stockholders Approve Directors and Auditor
5M ago
8K
KYTX
Kyverna Therapeutics Names Gregory Martini as New CFO
PremiumCompany Announcements
Kyverna Therapeutics Names Gregory Martini as New CFO
5M ago
8K
KYTX
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
PremiumThe Fly
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
5M ago
IRWD
KYTX
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
PremiumThe FlyKyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
5M ago
KYTX
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
Premium
The Fly
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
5M ago
KYTX
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
Premium
The Fly
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
5M ago
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >